What Gland Pharma Holders Bought Into Before An 80% Run

If you had backed Gland Pharma at the very start of 2026, the outcome would look very different today. Holding Gland Pharma from the start of the year would have returned 80.2%, including dividends. That result now throws the original fork in the road into sharp relief. If you were weighing rapid GLP-1 capacity expansion against the risk of overbuilding and margin pressure back then, which side of that debate had the stronger case on record?

Gland Pharma has already moved. See which of 201 high quality undervalued stocks still trade below our estimates.

The Argument You Would Have Been Weighing On Gland Pharma

The shares cost ₹1,715 at the start of the period, and anyone looking at Gland Pharma then had to choose between two very different stories about its future.

The bullish narrative described potential upside to a Fair Value of ₹1,863. This was a rough guide to what the stock might be worth if things played out as expected, based on 14.5% assumed annual revenue growth and profit margins reaching 19.7% within three years.

The bearish view instead pointed to a Fair Value of ₹1,138 and focused on the risk that GLP-1 capacity would climb to 140 million units while demand lagged, leaving expensive new facilities underused and margins under strain.

What The Results Changed For Gland Pharma

The clearest new data point on Gland Pharma came from Q1 2027, where revenue was ₹18,002.71m versus ₹15,056.22m a year earlier and net income was ₹3,169.59m versus ₹2,154.82m. Net margin moved from 14.3% to 17.6%. Higher sales and a thicker margin supported the view that capacity investment could help maintain profitability.

The takeaway is simple. When an investment thesis focuses on margins, track the net margin line first. After that, compare it with revenue and earnings trends in later filings for any other stock you study.

What Gland Pharma's Price Now Asks You To Believe

Gland Pharma now trades at ₹3,067 from the start of the year, and the selected Narrative’s Fair Value sits below that quote, which frames today’s level as demanding rather than cheap.

The Narrative focuses on execution on CDMO expansion and complex injectables. A buyer at this level is effectively assuming higher utilization and margins, and then has to weigh how the highlighted timing and regulatory risks might affect that path.

"While Gland Pharma is investing heavily in complex injectable platforms and advanced delivery systems, with commercialization guided around FY 2028 to FY 2030, the company’s own indication that GLP 1 related revenues will be very limited over the next three years points to a long gap before these projects materially contribute, which could restrain revenue growth and delay the uplift in net margins investors expect from higher value products."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

How Could You Get There Earlier?

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

• Company 1 - 41% below our estimate - supplies treatment-planning and oncology-workflow software hospitals use to replace legacy systems.
• Company 2 - 45% below our estimate - uses data and AI tools to refine underwriting and claims handling for select portfolios.
• Company 3 - 46% below our estimate - pushes AI-based security platforms that convert software buyers into higher-margin ARR customers.

Those are three of them. See all 197 companies with the balance sheet to back it up →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com